Multiple Myeloma Clinical Trials

A listing of 189 Multiple Myeloma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Multiple Myeloma

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 189 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

NCT05675449

Recruiting

The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optim... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/30/2025

Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +27 locations

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Beverly Hills Cancer Center, Beverly Hills, California

Sylvester Comprehensive Cancer Center - Aventura, Aventura, Florida

Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center, Coral Gables, Florida

Sylvester Comprehensive Cancer Center - Coral Springs, Coral Springs, Florida

University of Miami Hospital and Clinics - Deerfield Beach, Deerfield Beach, Florida

Sylvester Comprehensive Cancer Center - Hollywood, Hollywood, Florida

Sylvester Comprehensive Cancer Center, Miami, Florida

University of Miami Hospital And Clinics, Miami, Florida

Sylvester Comprehensive Cancer Center - Kendall, Miami, Florida

Sylvester Comprehensive Cancer Center - Plantation, Plantation, Florida

Emory University Hospital Midtown, Atlanta, Georgia

Emory University Hospital, Atlanta, Georgia

Winship Cancer Institute, Atlanta, Georgia

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Oncology Investigational Drug Service,Department of Pharmacy Services, Baltimore, Maryland

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

MSK Monmouth, Middletown, New Jersey

Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York, New York

Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York

Henry-Joyce Cancer Clinic, Nashville, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

Rambam Health Care Campus, Haifa, Not set

Division of Hematology Hadassah Medical Center - Ein Kerem, Jerusalem, Not set

Hematology Division Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Not set

The Chaim Sheba Medical Center, Ramat-Gan, Not set

Tel-Aviv Sourasky Medical Center, Tel Aviv, Not set

Conditions: Multiple Myeloma

Learn More ›

A Study of Talquetamab for People with Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

NCT06066346

Recruiting

The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/30/2025

Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations

Conditions: Multiple Myeloma

Learn More ›

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

NCT01838512

Recruiting

The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/28/2025

Locations: Local Institution, Birmingham, Alabama +197 locations

Local Institution, Birmingham, Alabama

Local Institution - 0021, Birmingham, Alabama

Local Institution - 0013, Muscle Shoals, Alabama

Local Institute, Goodyear, Arizona

Local Institution - 0023, Anaheim, California

Local Institution, Anaheim, California

Local Institution - 0045, Burbank, California

Local Institution, Corona, California

Local Institution - 0048, Downey, California

Local Institution - 0052, Fountain Valley, California

Local Institute, Los Angeles, California

Local Institute, Santa Rosa, California

Local Institution - 0051, Santa Rosa, California

Local Institution - 0057, Washington, District of Columbia

Florida Cancer Specialists & Research Institute, Brooksville, Florida

Local Institution, Brooksville, Florida

Local Institution - 0044, Fort Lauderdale, Florida

Local Institution - 0017, Jacksonville, Florida

Local Institution, Jacksonville, Florida

Local Institution - 0046, Savannah, Georgia

Local Institute, Valdosta, Georgia

Local Institution - 0047, Valdosta, Georgia

Local Institution, Skokie, Illinois

Local Institution - 0041, Springfield, Illinois

Local Institution - 0012, Urbana, Illinois

Local Institution - 0058, Anderson, Indiana

Local Institution - 0011, Indianapolis, Indiana

Local Institution, Indianapolis, Indiana

Local Institution - 0061, Des Moines, Iowa

Local Institute, Sioux City, Iowa

Local Institution - 0018, Sioux City, Iowa

Local Institution - 0062, Lexington, Kentucky

Local Institution - 0064, London, Kentucky

Local Institute, Louisville, Kentucky

Local Institution - 0042, Louisville, Kentucky

Cancer Center of Acadiana at Lafayette General Health, Lafayette, Louisiana

Local Institution, Lafayette, Louisiana

Local Institution - 0009, Shreveport, Louisiana

Local Institution, Shreveport, Louisiana

Local Institution, Minneapolis, Minnesota

Local Institution - 0030, Woodbury, Minnesota

Local Institution - 0059, Jackson, Mississippi

Local Institute, Southaven, Mississippi

Local Institute, Kansas City, Missouri

Local Institution - 0050, Kansas City, Missouri

Local Institution - 0037, Missoula, Missouri

Local Institute, Saint Joseph, Missouri

Local Institution - 0015, Saint Louis, Missouri

Local Institution, Saint Louis, Missouri

Local Institution - 0020, Springfield, Missouri

Local Institution, Springfield, Missouri

Local Institute, Missoula, Montana

Local Institution - 0060, Lincoln, Nebraska

Local Institute, Omaha, Nebraska

Local Institution - 0024, Omaha, Nebraska

Local Institution - 008, Does Not Exist, New Jersey

Generic Country - Canada, No City Provided, New Jersey

Generic Country - France, No City Provided, New Jersey

Generic Country - Germany, No City Provided, New Jersey

Generic Country - Italy, No City Provided, New Jersey

Generic Country - UK, No City Provided, New Jersey

Generic Country - USA, No City Provided, New Jersey

Local Institution - 0049, Stony Brook, New York

Local Institute, Cary, North Carolina

Local Institution - 0033, Cary, North Carolina

Local Institution - 0010, Gastonia, North Carolina

Local Institution, Gastonia, North Carolina

Local Institute, Canton, Ohio

Local Institution - 0022, Canton, Ohio

Local Institute, Cleveland, Ohio

Local Institution - 0019, Cleveland, Ohio

Local Institute, Tulsa, Oklahoma

Tulsa Cancer Institute PLLC, Tulsa, Oklahoma

Local Institute, Portland, Oregon

Local Institute, Pottstown, Pennsylvania

Local Institution - 0043, Pottstown, Pennsylvania

Local Institute, Charleston, South Carolina

Local Institution - 0016, Charleston, South Carolina

Local Institute, Knoxville, Tennessee

Local Institution - 0038, Knoxville, Tennessee

Local Institution - 0035, Memphis, Tennessee

Local Institution, Memphis, Tennessee

Local Institute, Amarillo, Texas

Local Institution - 0029, Amarillo, Texas

Local Institution - 0063, Bryan, Texas

Local Institute, Corpus Christi, Texas

Local Institute, Dallas, Texas

Local Institution - 0025, Dallas, Texas

Local Institute, Dallas, Texas

Local Institution - 0014, Dallas, Texas

Local Institution - 0032, Garland, Texas

Local Institute, San Antonio, Texas

Local Institution - 0027, San Antonio, Texas

Local Institute, Sherman, Texas

Local Institution - 0028, Sherman, Texas

Local Institute, Seattle, Washington

Local Institution - 0039, Seattle, Washington

Local Institute, Spokane, Washington

Local Institution - 0026, Spokane, Washington

Local Institute, Yakima, Washington

Local Institution - 0031, Yakima, Washington

Local Institution - 0065, Toronto, Ontario

Local Institute, Toronto, Ontario

Local Institution - 0066, Toronto, Ontario

Local Institute, Weston, Ontario

Local Institute, Blois, Not set

Local Institution - 0106, Cannes Cedex, Not set

Local Institution - 0099, Chalon sur Saone, Not set

Local Institute, Chalon sur Saone, Not set

Local Institute, La Roche sur Yon, Not set

Local Institution - 0100, La Roche-sur-yon Cedex 9, Not set

Local Institution - 0104, Limoges, Not set

Local Institute, Limoges, Not set

Local Institution - 0105, Meaux, Not set

Local Institute, Meaux, Not set

Local Institution - 0102, Nantes, Not set

Local Institute, Nantes, Not set

Local Institution - 0101, Perigueux, Not set

Local Institute, Rennes, Not set

Local Institution - 0103, Rennes, Not set

Local Institute, Heidelberg, Baden-Württemberg

Local Institute, Hamm, Nordrhein-Westfalen

Local Institute, Aschaffenburg, Not set

Local Institution - 0072, Aschaffenburg, Not set

Local Institute, Berlin, Not set

Local Institution - 0068, Berlin, Not set

Local Institution - 0081, Bielefeld, Not set

Local Institution, Bochum, Not set

Local Institute, Dresden, Not set

Local Institution - 0069, Dresden, Not set

Local Institution - 0082, Dresden, Not set

Local Institution - 0077, Frankfurt-oder, Not set

Local Institution - 0084, Gelsenkirchen, Not set

Local Institution - 0089, Goslar, Not set

Local Institution - 0070, Hamm, Not set

Local Institution - 0071, Heidelberg, Not set

Local Institution - 0088, Kiel, Not set

Local Institution - 0087, Köln, Not set

Local Institution - 0076, Ludwigsburg, Not set

Local Institute, Magdeburg, Not set

Local Institution - 0067, Magdeburg, Not set

Local Institution - 0073, Muenchen, Not set

Local Institution - 0079, Mutlangen, Not set

Local Institute, München, Not set

Local Institution - 0080, Oldenburg, Not set

Local Institution - 0075, Reutlingen, Not set

Local Institution - 0074, Rostock, Not set

Local Institution - 0086, Rostock, Not set

Local Institute, Rostock, Not set

Local Institution - 0078, Traunstein, Not set

Local Institution - 0085, Wiesbaden, Not set

Local Institute, Pesaro, Pesaro E Urbino

Local Institute, Ancona, Not set

Local Institution - 0108, Ancona, Not set

Local Institute, Ancona, Not set

Local Institution - 0119, Cagliari, Not set

Local Institute, Cagliari, Not set

Local Institution - 0111, Firenze, Not set

Local Institute, Firenze, Not set

Local Institute, Lecce, Not set

Local Institution - 0113, Lecce, Not set

Local Institution - 0124, Messina, Not set

Local Institution - 0120, Messina, Not set

Local Institute, Milano, Not set

Local Institution - 0116, Milano, Not set

Local Institute, Napoli, Not set

Local Institution - 0114, Napoli, Not set

Local Institution - 0115, Pesaro, Not set

Local Institution - 0121, Pescara, Not set

Local Institute, Roma, Not set

Local Institution - 0109, Roma, Not set

Local Institution - 0110, Roma, Not set

Local Institution - 0118, Roma, Not set

Local Institution, Roma, Not set

Local Institution - 0122, San Giovanni Rotondo (FG), Not set

Local Institution - 0107, Terni, Not set

Local Institute, Terni, Not set

Local Institute, Torino, Not set

Local Institution - 0112, Torino, Not set

Local Institute, Vicenza, Not set

Local Institution - 0117, Vicenza, Not set

Local Institute, Truro, Cornwall

Local Institution - 0098, Harrow, Greater London

Local Institute, Leeds, Not set

Local Institution - 0092, Leeds, Not set

Local Institution - 0091, Liverpool, Not set

Local Institution, Liverpool, Not set

Local Institution - 0097, Manchester, Not set

Local Institute, Nottingham, Not set

Local Institution - 0095, Nottingham, Not set

Local Institute, Stafford, Not set

Local Institution - 0096, Stafford, Not set

Local Institute, Swansea, Not set

Local Institution - 0093, Swansea, Not set

Local Institution - 0094, Truro, Not set

Conditions: Multiple Myeloma

Learn More ›

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients with Advanced Cancer

NCT05969860

Recruiting

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted in infusion centers or specialty hospitals, where patients spend many hours a day isolated from family, friends, and familiar surroundings. This separation adds to the physical, emotional, social, and... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/27/2025

Locations: Mayo Clinic in Florida, Jacksonville, Florida +1 locations

Conditions: Advanced Malignant Solid Neoplasm, Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma, Advanced Carcinoid Tumor, Advanced Cervical Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastric Carcinoma, Advanced Glioblastoma, Advanced Head and Neck Carcinoma, Advanced HER2 Positive Breast Carcinoma, Advanced Lung Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Germ Cell Tumor, Advanced Neuroendocrine Carcinoma, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Prostate Small Cell Neuroendocrine Carcinoma, Hematopoietic and Lymphoid System Neoplasm, Multiple Myeloma, Myelodysplastic Syndrome

Learn More ›

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

NCT05497804

Recruiting

This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help determine if patients who have a small amount of cancer left after the initial treatment, called m... Read More

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

01/27/2025

Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations

Conditions: ISS Stage III Plasma Cell Myeloma, Multiple Myeloma

Learn More ›

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

NCT04975555

Recruiting

This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematological malignancies.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/24/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama

Conditions: Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia

Learn More ›

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

NCT05706766

Recruiting

The goal of this research study is to investigate whether a virtual, home-based, prehabilitation aerobic and resistance exercise (PARE) training program implemented 8 weeks prior to receiving autologous stem cell transplant (ASCT) for multiple myeloma participants will improve muscular strength, physical capacity, patient reported outcomes, and cardiometabolic health outcomes. The names of the study interventions involved in this study are: * Prehabilitative aerobic and resistance exercise (PA... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: Dana Farber Cancer Institute, Boston, Massachusetts +1 locations

Conditions: Multiple Myeloma, Stem Cell Transplant Complications

Learn More ›

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

NCT06296368

Recruiting

The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatment decisions compared to usual care.

Gender:

ALL

Ages:

60 years and above

Trial Updated:

01/23/2025

Locations: Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

Conditions: Hematologic Malignancies, Lymphoma, Multiple Myeloma, Leukemia, Blood Cancers

Learn More ›

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients with Renal Insufficiency

NCT04240054

Recruiting

This is a single-arm, open-label phase II study with a safety lead-in phase.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/22/2025

Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin

Conditions: Multiple Myeloma

Learn More ›

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

NCT00582621

Recruiting

The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder such as lymphoma, leukemia, or multiple myeloma, and have a family member with one of these disorders or 2) they are a member of a family with a lymphoproliferative disorder, including Hodgkin's disease a... Read More

Gender:

ALL

Ages:

All

Trial Updated:

01/21/2025

Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +5 locations

Conditions: Lymphoma, Leukemia, Multiple Myeloma, Colon Cancer, Renal Cancer

Learn More ›

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083

Recruiting

The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/21/2025

Locations: University of Arkansas, Little Rock, Arkansas +140 locations

University of Arkansas, Little Rock, Arkansas

City of Hope, Duarte, California

UC San Diego Health Moores Cancer Center, San Diego, California

University of California San Francisco (UCSF), San Francisco, California

Stanford University, Stanford, California

Moffitt Cancer Center, Tampa, Florida

Emory University Hospital, Atlanta, Georgia

University of Chicago, Chicago, Illinois

University of Iowa, Iowa City, Iowa

The University of Kansas Cancer Center, Kansas City, Kansas

University of Maryland Medical Center, Baltimore, Maryland

University Of Maryland Medical Center, Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Boston Medical Center, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Dana Farber Cancer Institute - Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Center, Detroit, Michigan

Karmanos Cancer Institute, Detroit, Michigan

Mayo Clinic Hospital - Rochester, Rochester, Minnesota

Montefiore M-E Center, Bronx, New York

Mount Sinai Medical Venter, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

University of Rochester, Rochester, New York

Levine Cancer Institute, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

Duke Cancer Institute, Durham, North Carolina

Cleveland Clinic, Cleveland, Ohio

The Ohio State University, Columbus, Ohio

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Univ. of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania

University of Texas Southwestern Medical Center, Dallas, Texas

University of Virginia, Charlottesville, Virginia

Fred Hutchinson Cancer Center, Seattle, Washington

University Of Washington - Medical Center, Seattle, Washington

University of Wisconsin Hospital and Clinics, Madison, Wisconsin

Medical College Wisconsin (MCOW), Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin

Medical College Wisconsin, Milwaukee, Wisconsin

Royal Adelaide Hospital, Adelaide, Not set

Princess Alexandra Hospital, Brisbane, Not set

Royal Prince Alfred Hospital, Camperdown, Not set

Royal Brisbane and Womens Hospital, Herston, Not set

Alfred Health, Melbourne, Not set

Austin Hospital, Melbourne, Not set

Peter MacCallum Cancer Centre, Melbourne, Not set

St. Vincent's Hospital, Melbourne, Not set

Fiona Stanley Hospital, Murdoch, Not set

Calvary Mater Newcastle Hospital, Waratah, Not set

Westmead Hospital, Westmead, Not set

Jules Bordet Instituut, Anderlecht, Not set

UZA, Antwerpen, Not set

UZ Gent, Gent, Not set

UZ Leuven, Leuven, Not set

Tom Baker Cancer Center, Calgary, Not set

Cross Cancer Institute, Edmonton, Not set

McMaster University, Hamilton, Not set

Hopital Maisonneuve-Rosemont, Montréal, Not set

Mcgill University Health Centre, Montréal, Not set

Ottawa Hospital Research Institute, Ottawa, Not set

(CHU) Centre Hospitalier Universitaire de Quebec Laval, Québec, Not set

Princess Margaret Cancer Centre, Toronto, Not set

Vancouver General Hospital, Vancouver, Not set

Fakultni nemocnice Brno, Brno, Not set

Fakultni nemocnice Hradec Kralove, Králová, Not set

Fakutni nemocnice Ostrava, Ostrava, Not set

Fakultni nemocnice Plzen, Plzen, Not set

Vseobecna fakultni nemocnice v Prague, Prague, Not set

CHRU de Lille - Hopital Claude Huriez, Lille, Not set

Hospices Civils De Lyon, Lyon, Not set

CHU De Nantes - Hématologie Clinique, Nantes, Not set

Aphp Direction, Paris, Not set

CHU Poitiers - Pôle régional de Cancérologie, Poitiers, Not set

Hopital Saint Louis - Aphp Hôpitaux Universitaires Saint-Louis, Saint-Louis, Not set

CHU de Toulouse, Toulouse, Not set

University Hospital of Cologne, Cologne, Not set

Dresden, Dresden, Not set

Universitätsklinikum Hamburg - Eppendorf, Hamburg, Not set

Nationales Centrum für Tumorerkrankungen (NCT) Abt. Medizinische Onkologie, Heidelberg, Not set

University Hospital of Leipzig, Leipzig, Not set

Tübingen, Tübingen, Not set

University Hospital of Würzburg, Würzburg, Not set

Attikon University General Hospital of Attica, Athens, Not set

'G. Papanikolaou' Hospital of Thessaloniki, Thessaloníki, Not set

Hadassah Medical Center, Jerusalem, Not set

Hadassah University Hospita - Ein Kerem, Jerusalem, Not set

Sheba Medical Center, Ramat Gan, Not set

Sheba medical center, Ramat Gan, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi Di Ancona, Ancona, Not set

Policlinico S Orsola Malpighi, Bologna, Not set

A.O.U. Policlinico S. Martino - Ematologia, Genova, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milan, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Milan, Not set

Fondazione Policlinico Universitario Agostino Gemelli, Roma, Not set

A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette, Turin, Turin, Not set

Juntendo University Hospital, Bunkyō-Ku, Not set

Kyushu University Hospital - Hematology/Oncology, Fukuoka, Not set

Hokkaido University Hospital-Department of Hematology, Hokkaido, Not set

Hyogo College of Medicine, Hyōgo, Not set

Kanazawa University Hospital, Kanazawa, Not set

Nagoya City University Hospital - Department of Hematology & Oncology, Nagoya, Not set

Okayama University Hospital - Hematology/Oncology, Okayama, Not set

Osaka metropolitan university hospital, Osaka, Not set

Japanese Red Cross Medical Center - Hematology, Shibuya, Not set

Keio University Hospital - Hematology, Shinjuku-Ku, Not set

Keio University Hospital - Hematology, Tokyo, Not set

Tohoku University Hospital - Hematology, Tōhoku, Not set

VU Medisch Centrum, Amsterdam, Not set

University Medical Center Groningen, Groningen, Not set

Radboud UMC, Nijmegen, Not set

Erasmus MC, Rotterdam, Not set

UMC Utrecht, Utrecht, Not set

Oslo University Hospital Ullevål - Oncology, Oslo, Not set

Hospital Universitario Germans Trias i Pujol, Badalona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Instituto Catalán de Oncología, Barcelona, Not set

Hospital Universitario Ramón y Cajal, Madrid, Not set

Hospital General Universitario Gregorio Marañón, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

CLINICA UNIV. DE NAVARRA, Pamplona, Pamplona, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital de Santiago de Compostela, Santiago De Compostela, Not set

Hospital Universitario Virgen del Rocío, Sevilla, Not set

Hospital Universitario la Fe, Valencia, Valencia, Not set

Sahlgrenska Universitetssjukhuset, Göteborg, Not set

Landstinget i Ostergotland-Universitetssjukhuset i Linkoping, Linköping, Not set

Skånes University Hospital Lund, Lund, Not set

Akademiska Sjukhuset, Uppsala, Not set

Universitaetsspital Basel - Zentrum fur Hamato-Onkologie, Basel, Not set

Bern Inselspital, Bern, Not set

Universitaetsspital Bern, Inselspital, Bern, Not set

Centre Hospitalier Universitaire Vaudois (CHUV)Département d'oncologie, Lausanne, Not set

Lausanne CHUV Département d'oncologie, Lausanne, Not set

Universitaetsspital Zuerich -Universitaeren Herzzentrum Zuerich, Zürich, Not set

UniversitaetsSpital Zürich, Zürich, Not set

Queen Elizabeth Medical Centre, Birmingham, Not set

University Hospital of Wales, Cardiff, Not set

Leeds Cancer Centre at St. James's University Hospital, Leeds, Not set

Conditions: Multiple Myeloma

Learn More ›

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

NCT06119685

Recruiting

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/20/2025

Locations: Valkyrie Clinical Trials, Los Angeles, California +11 locations

Conditions: NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

Learn More ›